Because CXCL12 is the target molecule of HIF-1α, the hypoxic condition resulting from bevacizumab treatment could lead the tumor cells to produce CXCL12, which would in turn prompt the CXCR4+ cells to migrate into the tumor (Figure 1). The gene discussed is HIF1A; the disease is neoplasm.